À¯ÀüÀÚ ÆíÁý ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : ±â¼úº°, Àü´Þ ¹æ¹ýº°, ¿ëµµº°, ¸ðµåº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
Genome Editing Market Size, Share & Trends Analysis Report By Technology, By Delivery Method, By Application, By Mode, By End Use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1726231
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 04¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 120 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¼¼°è À¯ÀüÀÚ ÆíÁý ½ÃÀå ±Ô¸ð´Â 2030³â¿¡ 250¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2030³â¿¡ °ÉÃÄ 16.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ Áøº¸ Áõ°¡, À¯ÀüüÇÐ »ê¾÷¿¡ ´ëÇÑ ÀÚ±Ý Á¶´Þ ¹× ÅõÀÚ Áõ°¡, À¯Àü ÁúȯÀÇ À¯º´·ü Áõ°¡, Ä¡·á ¹× Ä¡·á °³¼±ÀÇ Çʿ伺Àº ¼öÀÍ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.
À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ ÁøÈ´Â ½ÃÀåÀÇ ¼öÀÍ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¶Ç ´Ù¸¥ ¿äÀÎÀÔ´Ï´Ù. Genomics¿Í New England BiolabÀº CRISPR À¯ÀüÀÚ º¯Çü µµ±¸ ¹× ½Ã¾à °³¹ß ¹× »ó¾÷ȸ¦ À§ÇØ Çù·ÂÇß½À´Ï´Ù.
À¯ÀüÀÚ º¯Çü µµ±¸ÀÇ Ä¡·á ¿¬±¸¿¡ ´ëÇÑ ÀÀ¿ëÀÌ ÁøÇàµÊ¿¡ µû¶ó ÀÓ»ó °Ë»ç¿¡ µé¾î°¡´Â ÷´Ü Ä¡·áÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº CRISPR°ú °°Àº À¯ÀüÀÚ º¯Çü ÀåÄ¡°¡ ´Ù¾çÇÑ ¸¸¼º ÁúȯÀÇ ½Å¼ÓÇÑ ½ºÅ©¸®´× ¼Ö·ç¼ÇÀÌ µÉ ¼ö ÀÖ´Â °¡´É¼ºÀ» ޱ¸Çϰí ÀÖ½À´Ï´Ù.
À¯ÀüÀÚ ÆíÁý ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- À¯ÀüÀÚ ÆíÁý ±â¼ú CRISPRÀº »ý¸í °øÇп¡¼ ±Þ¼ºÀå ±â¼úÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
- À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ ±Þ¼ÓÇÑ Áøº¸´Â Ä¡·áÀÇ Àü¸ÁÀ» À籸ÃàÇØ, ±¤¹üÀ§ÇÑ À¯Àü¼º Áúȯ, Ç÷¾× Áúȯ, ´ë»ç¼º Áúȯ, °¨¿°¼º ÁúȯÀÇ Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÑ ÀÓ»ó °Ë»çÀÇ ±ÞÁõÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
- »ýü ³» À¯Àüü ÆíÁýÀº Àü ¼¼°è Ä¡·á ȯ°æ¿¡¼ Çõ½ÅÀûÀÎ ÈûÀ¸·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù.ÀüÅëÀûÀÎ »ýü ¿Ü ¹æ¹ý°ú ´Þ¸®, »ýü ³» Á¢±Ù¹ýÀº ȯÀÚÀÇ ¸ö ¾È¿¡¼ Á÷Á¢ À¯ÀüÀÚ¸¦ ¼öÁ¤ÇÒ ¼ö ÀÖ°Ô ÇÏ¿© º¹ÀâÇÑ ¼¼Æ÷ ÃßÃâ, Á¶ÀÛ ¹× ÀçÀ¶ÇÕÀÇ Çʿ伺À» ¾ø¾ÖÁÝ´Ï´Ù.
- CRISPR/Cas9 ºÎ¹®Àº 2024³â ¼¼°è ¸ÅÃâ¿¡¼ 44.36%ÀÇ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
-
ºÏ¹ÌÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀåÀº À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ ¿¬±¸ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ¼¼°è ½ÃÀåÀ» µ¶Á¡Çϰí, 2024³â¿¡´Â 44.59%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅëÀÇ Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã, º¸Á¶ÀûÀÎ ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- À¯ÀüÀÚ ÆíÁý ½ÃÀå ºÐ¼® µµ±¸
- »ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- COVID-19ÀÇ ¿µÇ⠺м®
Á¦4Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå : ±â¼úº°, ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ ±â¼ú º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(±â¼úº°, 2018-2030³â)
- (Å©¸®½ºÆÛ)/Cas9
- TALEN/¸Þ°¡ TAL
- ZFN
- ¸Þ°¡´ºÅ¬·¹¾ÆÁ¦
- ±âŸ
Á¦5Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå : Àü´Þ ¹æ¹ý ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ Àü´Þ ¹æ¹ý º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(Àü´Þ ¹æ¹ýº°, 2018-2030³â)
- »ýü¿Ü
- »ýü³»
Á¦6Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå : ¿ëµµ ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ ¿ëµµ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(¿ëµµº°, 2018-2030³â)
- À¯ÀüÀÚ °øÇÐ
- ¼¼Æ÷ÁÖ °øÇÐ
- µ¿¹°À¯Àü°øÇÐ
- ½Ä¹°¼º ±â¸§Àü°øÇÐ
- ±âŸ
- ÀÓ»ó¿ëµµ
Á¦7Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå : ¸ðµå ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ ¸ðµå º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(¸ðµåº°, 2018-2030³â)
- °è¾à
- »ç³»
Á¦8Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(ÃÖÁ¾ ¿ëµµº°, 2018-2030³â)
- »ý¸í°øÇаú Á¦¾àȸ»ç
- Çмú±â°ü°ú Á¤ºÎ¿¬±¸±â°ü
- °è¾à ¿¬±¸ ±â°ü
Á¦9Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå : Áö¿ªº°, ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â°ú 2030³â
- Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ³ë¸£¿þÀÌ
- ½º¿þµ§
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- Çѱ¹
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦10Àå °æÀï ±¸µµ
- ±â¾÷/°æÀïÀÇ ºÐ·ù
- Àü·« ¸ÅÇÎ
- ±â¾÷½ÃÀå Æ÷Áö¼Å´× ºÐ¼®, 2024³â
- ±â¾÷ ÇÁ·ÎÆÄÀÏ/»óÀå ±â¾÷
- Merck KGaA
- Takara Bio Inc.
- Revvity, Inc.
- Danaher Corporation
- GenScript
- New England Biolabs
- Charles River Laboratories
- Eurofins Scientific
- Lonza
- Thermo Fisher Scientific, Inc.
SHW
¿µ¹® ¸ñÂ÷
Genome Editing Market Growth & Trends:
The global genome editing market size is expected to reach USD 25.00 billion in 2030 and is projected to grow at a CAGR of 16.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing advancements in genome editing technology, the growing funding & investments in the genomics industry, the increasing prevalence of genetic disorders, and the need for improved treatments and therapies are major factors driving revenue growth.
The evolution of genome editing technologies is another contributing factor to drive revenue growth in the market. Most effective and accurate gene editing is now possible through the enhancement of new and advanced genome editing methods including CRISPR-Cas13,prime editing, and base editing, amongst others. This creates genome editing methods used more often in academic and medical contexts. For instance, in January 2020, ERS Genomics and New England Biolab collaborated to develop and commercialize CRISPR gene modification tools & reagents.
The increasing application of gene-modification tools in therapeutic research has resulted in the rising number of advanced therapeutics entering clinical trials. Furthermore, the use of artificial intelligence to advance the implementation of novel gene modification systems exhibits great potential for the technology developer. This is anticipated to greatly favor revenue generation in the foreseeable future. Research communities are exploring the potential of gene-modification instruments such as CRISPR as a potential fast screening solution for various chronic diseases. Such research programs are likely to benefit the market for genome editing in the coming years.
Genome Editing Market Report Highlights:
- Gene editing technology CRISPR is projected to be the burgeoning technology in biotechnology. CRISPR harnesses the bacterial immune system to either knock genes out or insert new genes.
- The rapid advancement of genome editing technologies is reshaping the therapeutic landscape, driving a surge in clinical trials aimed at treating a wide range of genetic, hematologic, metabolic, and infectious diseases.
- In vivo genome editing is emerging as a transformative force within the global therapeutic landscape. Unlike traditional ex vivo methods, in vivo approaches allow for direct gene modification inside the patient's body, eliminating the need for complex cell extraction, manipulation, and reinfusion.
- The CRISPR/Cas9 segment held the largest market share of 44.36% of the global revenue in 2024. This can be attributed to high precision & efficiency, high versatility & adaptability to different experimental designs, and cost-effectiveness with relatively low expense associated
- North America genome editing market dominated the global market and accounted for a 44.59% share in 2024, owing to the growing investments in the R&D of gene editing technologies.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Technology Segment
- 1.2.2. Delivery Method Segment
- 1.2.3. Application Segment
- 1.2.4. Mode Segment
- 1.2.5. End-use Segment
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
Chapter 3. Genome Editing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Success in pre-clinical models drives demand for genome editing therapeutics
- 3.2.1.2. Rising competition amongst market participants for business development
- 3.2.1.3. Easy editing solutions for the development of therapeutics for a broad range of diseases
- 3.2.1.4. Increasing demand for synthetic genes and genetically modified organisms
- 3.2.1.5. Technological advancements in gene editing technologies
- 3.2.1.6. Rising adoption in agricultural biotechnology
- 3.2.2. Market restraint analysis
- 3.2.2.1. Challenges concerning clinical translation
- 3.2.2.2. Regulatory, scientific, and ethical challenges regarding the use of genetically modified products
- 3.2.2.3. Off-target effects of CRISPR technology
- 3.3. Genome Editing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Genome Editing Market: Technology Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Genome Editing Market Technology Movement Analysis
- 4.3. Global Genome Editing Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
- 4.4. (CRISPR)/Cas9
- 4.4.1. (CRISPR)/Cas9 market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. TALENs/MegaTALs
- 4.5.1. TALENs/MegaTALs market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. ZFN
- 4.6.1. ZFN market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Meganuclease
- 4.7.1. Meganuclease market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Others
- 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Genome Editing Market: Delivery Method Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Genome Editing Market Delivery Method Movement Analysis
- 5.3. Global Genome Editing Market Size & Trend Analysis, by Delivery Method, 2018 to 2030 (USD Million)
- 5.4. Ex Vivo
- 5.4.1. Ex vivo market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. In-Vivo
- 5.5.1. In-vivo market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Genome Editing Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Genome Editing Market Application Movement Analysis
- 6.3. Global Genome Editing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 6.4. Genetic Engineering
- 6.4.1. Genetic Engineering market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.2. Cell Line Engineering
- 6.4.2.1. Cell line engineering market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.3. Animal Genetic Engineering
- 6.4.3.1. Animal genetic engineering market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.4. Plant Genetic Engineering
- 6.4.4.1. Plant genetic engineering market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.5. Others
- 6.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Clinical Applications
- 6.5.1. Clinical applications market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.2. Diagnostics Development
- 6.5.2.1. Diagnostics development market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.3. Therapy Development
- 6.5.3.1. Therapy development market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Genome Editing Market: Mode Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Genome Editing Market Mode Movement Analysis
- 7.3. Global Genome Editing Market Size & Trend Analysis, by Mode, 2018 to 2030 (USD Million)
- 7.4. Contract
- 7.4.1. Contract market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. In-house
- 7.5.1. In-house market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Genome Editing Market: End-Use Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Global Genome Editing Market End-Use Movement Analysis
- 8.3. Global Genome Editing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
- 8.4. Biotechnology and pharmaceutical companies
- 8.4.1. Biotechnology and pharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5. Academic and government research institutes
- 8.5.1. Academic and government research institutes market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6. Contract research organizations
- 8.6.1. Contract research organizations market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Genome Editing Market: Regional Estimates & Trend Analysis
- 9.1. Regional Market Share Analysis, 2024 & 2030
- 9.2. Regional Market Dashboard
- 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 9.4. North America
- 9.4.1. U.S.
- 9.4.1.1. Key country dynamics
- 9.4.1.2. Regulatory framework
- 9.4.1.3. Target disease prevalence
- 9.4.1.4. Competitive scenario
- 9.4.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.2. Canada
- 9.4.2.1. Key country dynamics
- 9.4.2.2. Regulatory framework
- 9.4.2.3. Target disease prevalence
- 9.4.2.4. Competitive scenario
- 9.4.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.3. Mexico
- 9.4.3.1. Key country dynamics
- 9.4.3.2. Regulatory framework
- 9.4.3.3. Target disease prevalence
- 9.4.3.4. Competitive scenario
- 9.4.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5. Europe
- 9.5.1. UK
- 9.5.1.1. Key country dynamics
- 9.5.1.2. Regulatory framework
- 9.5.1.3. Target disease prevalence
- 9.5.1.4. Competitive scenario
- 9.5.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.2. Germany
- 9.5.2.1. Key country dynamics
- 9.5.2.2. Regulatory framework
- 9.5.2.3. Target disease prevalence
- 9.5.2.4. Competitive scenario
- 9.5.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.3. France
- 9.5.3.1. Key country dynamics
- 9.5.3.2. Regulatory framework
- 9.5.3.3. Target disease prevalence
- 9.5.3.4. Competitive scenario
- 9.5.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.4. Italy
- 9.5.4.1. Key country dynamics
- 9.5.4.2. Regulatory framework
- 9.5.4.3. Target disease prevalence
- 9.5.4.4. Competitive scenario
- 9.5.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.5. Spain
- 9.5.5.1. Key country dynamics
- 9.5.5.2. Regulatory framework
- 9.5.5.3. Target disease prevalence
- 9.5.5.4. Competitive scenario
- 9.5.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.6. Norway
- 9.5.6.1. Key country dynamics
- 9.5.6.2. Regulatory framework
- 9.5.6.3. Target disease prevalence
- 9.5.6.4. Competitive scenario
- 9.5.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.7. Sweden
- 9.5.7.1. Key country dynamics
- 9.5.7.2. Target disease prevalence
- 9.5.7.3. Regulatory framework
- 9.5.7.4. Competitive scenario
- 9.5.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.8. Denmark
- 9.5.8.1. Key country dynamics
- 9.5.8.2. Regulatory framework
- 9.5.8.3. Target disease prevalence
- 9.5.8.4. Competitive scenario
- 9.5.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 9.6. Asia Pacific
- 9.6.1. Japan
- 9.6.1.1. Key country dynamics
- 9.6.1.2. Regulatory framework
- 9.6.1.3. Target disease prevalence
- 9.6.1.4. Competitive scenario
- 9.6.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 9.6.2. China
- 9.6.2.1. Key country dynamics
- 9.6.2.2. Regulatory framework
- 9.6.2.3. Target disease prevalence
- 9.6.2.4. Competitive scenario
- 9.6.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
- 9.6.3. India
- 9.6.3.1. Key country dynamics
- 9.6.3.2. Regulatory framework
- 9.6.3.3. Competitive scenario
- 9.6.3.4. Target disease prevalence
- 9.6.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
- 9.6.4. Australia
- 9.6.4.1. Key country dynamics
- 9.6.4.2. Regulatory framework
- 9.6.4.3. Target disease prevalence
- 9.6.4.4. Competitive scenario
- 9.6.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 9.6.5. South Korea
- 9.6.5.1. Key country dynamics
- 9.6.5.2. Regulatory framework
- 9.6.5.3. Target disease prevalence
- 9.6.5.4. Competitive scenario
- 9.6.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 9.6.6. Thailand
- 9.6.6.1. Key country dynamics
- 9.6.6.2. Target disease prevalence
- 9.6.6.3. Regulatory framework
- 9.6.6.4. Competitive scenario
- 9.6.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 9.7. Latin America
- 9.7.1. Brazil
- 9.7.1.1. Key country dynamics
- 9.7.1.2. Regulatory framework
- 9.7.1.3. Target disease prevalence
- 9.7.1.4. Competitive scenario
- 9.7.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 9.7.2. Argentina
- 9.7.2.1. Key country dynamics
- 9.7.2.2. Regulatory framework
- 9.7.2.3. Target disease prevalence
- 9.7.2.4. Competitive scenario
- 9.7.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 9.8. MEA
- 9.8.1. South Africa
- 9.8.1.1. Key country dynamics
- 9.8.1.2. Regulatory framework
- 9.8.1.3. Competitive scenario
- 9.8.1.4. Target disease prevalence
- 9.8.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 9.8.2. Saudi Arabia
- 9.8.2.1. Key country dynamics
- 9.8.2.2. Regulatory framework
- 9.8.2.3. Target disease prevalence
- 9.8.2.4. Competitive scenario
- 9.8.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 9.8.3. UAE
- 9.8.3.1. Key country dynamics
- 9.8.3.2. Regulatory framework
- 9.8.3.3. Target disease prevalence
- 9.8.3.4. Competitive scenario
- 9.8.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 9.8.4. Kuwait
- 9.8.4.1. Key country dynamics
- 9.8.4.2. Regulatory framework
- 9.8.4.3. Target disease prevalence
- 9.8.4.4. Competitive scenario
- 9.8.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Company/Competition Categorization
- 10.2. Strategy Mapping
- 10.3. Company Market Position Analysis, 2024
- 10.4. Company Profiles/Listing
- 10.4.1. Merck KGaA
- 10.4.1.1. Company overview
- 10.4.1.2. Financial performance
- 10.4.1.3. Product benchmarking
- 10.4.1.4. Strategic initiatives
- 10.4.2. Takara Bio Inc.
- 10.4.2.1. Company overview
- 10.4.2.2. Financial performance
- 10.4.2.3. Product benchmarking
- 10.4.2.4. Strategic initiatives
- 10.4.3. Revvity, Inc.
- 10.4.3.1. Company overview
- 10.4.3.2. Financial performance
- 10.4.3.3. Product benchmarking
- 10.4.3.4. Strategic initiatives
- 10.4.4. Danaher Corporation
- 10.4.4.1. Company overview
- 10.4.4.2. Financial performance
- 10.4.4.3. Product benchmarking
- 10.4.4.4. Strategic initiatives
- 10.4.5. GenScript
- 10.4.5.1. Company overview
- 10.4.5.2. Financial performance
- 10.4.5.3. Product benchmarking
- 10.4.5.4. Strategic initiatives
- 10.4.6. New England Biolabs
- 10.4.6.1. Company overview
- 10.4.6.2. Financial performance
- 10.4.6.3. Product benchmarking
- 10.4.6.4. Strategic initiatives
- 10.4.7. Charles River Laboratories
- 10.4.7.1. Company overview
- 10.4.7.2. Financial performance
- 10.4.7.3. Product benchmarking
- 10.4.7.4. Strategic initiatives
- 10.4.8. Eurofins Scientific
- 10.4.8.1. Company overview
- 10.4.8.2. Financial performance
- 10.4.8.3. Product benchmarking
- 10.4.8.4. Strategic initiatives
- 10.4.9. Lonza
- 10.4.9.1. Company overview
- 10.4.9.2. Financial performance
- 10.4.9.3. Product benchmarking
- 10.4.9.4. Strategic initiatives
- 10.4.10. Thermo Fisher Scientific, Inc.
- 10.4.10.1. Company overview
- 10.4.10.2. Financial performance
- 10.4.10.3. Product benchmarking
- 10.4.10.4. Strategic initiatives
°ü·ÃÀÚ·á